2484719-17-5O-Chlorobutylabiraterone
● Under Development
| Catalogue No.: | VL830019 |
|---|---|
| CAS No.: | 2484719-17-5 |
| Mol. Formula: | C28H38ClNO |
| Mol. Weight: | 440.07 g/mol |
Additional information on CAS 2484719-17-5
Parent drug
AbirateroneIUPAC Name
3β-(4-Chlorobutoxyl)-17-(Pyridin-3-yl)androsta-5, 16-dienePharmacopoeial Synonyms
N/AOther Synonyms
Chlorobutoxy Abiraterone;Pyridine, 3-(3-(4-chlorobutoxy)androsta-5,16-dien-17-yl)Smiles
C[C@]12CC[C@@H](CC1=CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC=C4C5=CN=CC=C5)C)OCCCCClInChI
InChI=1S/C28H38ClNO/c1-27-13-11-22(31-17-4-3-15-29)18-21(27)7-8-23-25-10-9-24(20-6-5-16-30-19-20)28(25,2)14-12-26(23)27/h5-7,9,16,19,22-23,25-26H,3-4,8,10-15,17-18H2,1-2H3/t22-,23-,25-,26-,27-,28+/m0/s1Description
O-Chlorobutylabiraterone is a meticulously characterized reference material that complies with rigorous regulatory requirements, including those defined by USP, EMA, JP, and BP. This product plays a crucial role in Abbreviated New Drug Applications (ANDA), New Drug Applications (NDA), and the commercial manufacturing of Abiraterone. It is further supported by a detailed Structure Elucidation Report (SER), ensuring high accuracy and reliability across a broad range of analytical applications. O-Chlorobutylabiraterone (CAS NO-2484719-17-5) is a steroidal compound with antiandrogen activity. Abiraterone is used to treat metastatic, castration-resistant prostate cancer mainly in patients who have undergone chemotherapy. Abiraterone acetate is a prodrug of abiraterone that blocks
References
Works Cited de Bono, Johann S., et al. “Abiraterone and Increased Survival in Metastatic Prostate Cancer.†New England Journal of Medicine, vol. 364, no. 21, 26 May 2011, pp. 1995–2005, 10.1056/nejmoa1014618.Request a Quote
"*" indicates required fields









